Home Publications Research Grants Inventions & Patents Awards Additional Research Activities Faculties & Institutions Research Areas

Correction to: Tivozanib Monotherapy in the Frontline Setting for Patients with Metastatic Renal Cell Carcinoma and Favorable Prognosis (Current Oncology Reports, (2024), 26, 12, (1639-1650), 10.1007/s11912-024-01613-7)

Frazer R, Arranz JÁ, Estévez SV, Parikh O, Krabbe LM, Vasudev NS, Doehn C, Marschner N, Waddell T, Ince W, Goebell P (2025)

---

Publication Type: Journal article, Erratum

Publication year: 2025

Journal

DOI: 10.1007/s11912-025-01670-6

Abstract

The original online version of this article was revised due to formatting errors introduced by the journal during typesetting. 1. Updates to the tables regarding bold emphasis and alignment have been made as shown below. Response and survival outcomes for the single-agent TKIs recommended by the European Society for Medical Oncology [3], the European Association of Urology [2], the National Comprehensive Cancer Network [4] and the German guidelines [5] in the frontline mRCC setting. Data in the table are based on the pivotal studies for cabozantinib [48, 49], pazopanib [43–45, 50, 72], sunitinib [46, 47, 51], and tivozanib [52, 53, 73] Cabozantinib Pazopanib Sunitinib Tivozanib ITT population 8.6 (6.8–14.0) 9.2 (7.4–12.9) 11.0 (10.0–12.0) 11.9 (9.3–14.7) MSKCC risk group Favorable n/a 14.8 (n=113 [39%] n/a 16.7 (n=70 [27%]) Intermediate n/a 5.6 (n=159 [54.8%]) n/a 9.4 (n=173 [67%]) Poor n/a Not reported n/a 3.7 (n=17 [7%]) IMDC risk group Favorable Excluded^a n/a 14.1 (n=134 [37.5%]) NE (16.7–NR) (n=41 [16%]) Intermediate 11.4 (n=64 [81.0%]) n/a 10.7 (n=205 [54.7%]) 13.0 (n=137 [53%]) Poor 6.8 (n=15 [19%]) n/a 2.4 (n=34 [11%]) Excluded^b (n=78 [30%]) ITT population 26.6 (14.6–NE) 22.9 26.4 (23.0–32.9) 28.8 (22.5–NE) Overall response rate 20 30 47 33 Complete response 0 <1 3 1 Partial response 20 30 44 32 Stable disease 54 38 40 52 Disease control rate 74 68 87 85 CI confidence interval, EAU European Association of Urology, ESMO European Society for Medical Oncology, IMDC International Metastatic RCC Database Consortium, ITT intention-to-treat, MSKCC Memorial Sloan Kettering Cancer Center, mRCC metastatic renal cell carcinoma, n/a not available, NCCN National Comprehensive Cancer Network, NE not estimable, NR not reached, OS overall survival, PFS progression-free survival ^aThe CABOSUN trial included patients with intermediate or poor risk but not favorable risk mRCC. ^bSample size too small Tolerability profiles for the single-agent TKIs recommended by the European Society for Medical Oncology [3], the European Association of Urology [2], the National Comprehensive Cancer Network [4] and the German guidelines [5] in the frontline mRCC setting. Data in table based on the pivotal studies for cabozantinib [48, 49], pazopanib [44], sunitinib [46, 47], and tivozanib [52] Cabozantinib Pazopanib Sunitinib Tivozanib Dose reductions (%) 46 NR 38 14 Dose interruptions (%) NR NR 32 19 Discontinuation due to AE (%) 20 14 8 4 Off-target AEs (%) Fatigue All grades 86 19 54 19 Grades 3/4 6 2 11 5 Hand-foot syndrome All grades 42 NR 29 14 Grades 3/4 8 NR 9 2 Diarrhea All grades 72 52 61 23 Grades 3/4 10 4 9 2 AE adverse event, EAU European Association of Urology, ESMO European Society for Medical Oncology, mRCC metastatic renal cell carcinoma, NCCN National Comprehensive Cancer Network, NR not reported 2. In the updated Figure 1 below, the spell-check markings (red underlines) have been removed. (Figure presented.) The original article has been corrected.

Authors with CRIS profile

Involved external institutions

How to cite

APA:

Frazer, R., Arranz, J.Á., Estévez, S.V., Parikh, O., Krabbe, L.M., Vasudev, N.S.,... Goebell, P. (2025). Correction to: Tivozanib Monotherapy in the Frontline Setting for Patients with Metastatic Renal Cell Carcinoma and Favorable Prognosis (Current Oncology Reports, (2024), 26, 12, (1639-1650), 10.1007/s11912-024-01613-7). Current Oncology Reports. https://doi.org/10.1007/s11912-025-01670-6

MLA:

Frazer, Ricky, et al. "Correction to: Tivozanib Monotherapy in the Frontline Setting for Patients with Metastatic Renal Cell Carcinoma and Favorable Prognosis (Current Oncology Reports, (2024), 26, 12, (1639-1650), 10.1007/s11912-024-01613-7)." Current Oncology Reports (2025).

BibTeX: Download